Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Oncogene

• Publication date

  2004-08-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1207813PMID 15208656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• STAT proteins: From normal control of cellular events to tumorigenesis

  2003cited by this paper
• Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma

  2003cited by this paper
• The oncogenic fusion protein nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model

  2003cited by this paper
• Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability*

  2003cited by this paper
• Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

  2002cited by this paper
• Activation of the PI3K/Akt pathway and chemotherapeutic resistance.

  2002cited by this paper
• Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor

  2002cited by this paper
• Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.

  2002cited by this paper
• Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types*

  2002cited by this paper
• Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase*

  2002cited by this paper
• Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth*

  2002cited by this paper
• Actin dynamics: tropomyosin provides stability.

  2002cited by this paper
• Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1

  2002cited by this paper
• Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*

  2001cited by this paper
• Dual role of H-Ras in regulation of lymphocyte function antigen-1 activity by stromal cell-derived factor-1alpha: implications for leukocyte transmigration.

  2001cited by this paper
• Translocations involving anaplastic lymphoma kinase (ALK)

  2001influential reference
• Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma

  2001cited by this paper
• Anaplastic large cell lymphoma: pathological, molecular and clinical features

  2001cited by this paper
• Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.

  2001influential reference
• Anaplastic large cell lymphoma: pathological, molecular and clinical features.

  2001cited by this paper
• ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

  2000cited by this paper
• Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.

  2000cited by this paper
• Phosphoinositide 3‐kinase: a key biochemical signal for cell migration in response to chemokines

  2000cited by this paper
• TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

  2000cited by this paper
• Expression of the ALK tyrosine kinase gene in neuroblastoma.

  2000cited by this paper
• Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).

  2000cited by this paper
• A New 34-Kilodalton Isoform of Human Fibroblast Growth Factor 2 Is Cap Dependently Synthesized by Using a Non-AUG Start Codon and Behaves as a Survival Factor

  1999cited by this paper
• A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.

  1999cited by this paper
• Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity

  1998cited by this paper
• Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

  1997cited by this paper
• Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.

  1997cited by this paper
• Protein expression changes associated with radiation‐induced neoplastic progression of human prostate epithelial cells

  1997cited by this paper
• ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

  1997cited by this paper
• Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

  1997cited by this paper
• Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

  1996cited by this paper
• Sequence Correction

  1995cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Chromosomal translocations in human cancer

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Restoration of microfilament bundle organization in v-raf-transformed NRK cells after transduction with tropomyosin 2 cDNA.

  1994cited by this paper
• Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about.

  1994cited by this paper
• Growth and death behaviour of anchorage-independent animal cells immobilized within porous support matrices

  1992cited by this paper
• Suppression of synthesis of tropomyosin isoform 2 in metastatic v-Ha-ras-transformed NIH3T3 cells.

  1988cited by this paper
• Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate

  1988influential reference
• Suppression of tropomyosin synthesis, a common biochemical feature of oncogenesis by structurally diverse retroviral oncogenes.

  1985cited by this paper
• Quantitative changes of tropomyosin synthesis in RSV-transformed mammalian cells in comparison with normal fibroblasts.

  1982cited by this paper
• Tropomyosin is decreased in transformed cells.

  1981cited by this paper

• ALK in cancer: from function to therapeutic targeting

  2025cites this paper
• ALK-positive adult histiocytosis with a TFG-ALKfusion gene

  2025cites this paper
• PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors

  2025cites this paper
• Mechanisms of tropomyosin 3 in the development of malignant tumors

  2024cites this paper
• Variant ALK‐fusion positive anaplastic large cell lymphoma (ALCL): A population‐based paediatric study of the NHL‐BFM study group

  2024cites this paper
• NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

  2024cites this paper
• Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion

  2023cites this paper
• Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants.

  2023cites this paper
• ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

  2023cites this paper
• Updates in pathobiological aspects of anaplastic large cell lymphoma

  2023influential citation
• TPM3: a novel prognostic biomarker of cervical cancer that correlates with immune infiltration and promotes malignant behavior in vivo and in vitro.

  2023cites this paper
• Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy

  2023cites this paper
• TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature

  2023cites this paper
• Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment

  2021cites this paper
• Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

  2021cites this paper
• Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer

  2021cites this paper
• Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review

  2021influential citation
• High Level of Staufen1 Expression Confers Longer Recurrence Free Survival to Non-Small Cell Lung Cancer Patients by Promoting THBS1 mRNA Degradation

  2021cites this paper
• Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review

  2020cites this paper
• EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53

  2020cites this paper
• Pediatric low-grade glioma in the era of molecular diagnostics

  2020cites this paper
• The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors.

  2020cites this paper
• Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.

  2020cites this paper
• dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers

  2020cites this paper
• The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

  2019influential citation
• A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

  2019cites this paper
• Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.

  2019cites this paper
• Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides

  2019cites this paper
• Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine

  2019cites this paper
• ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

  2018cites this paper
• Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

  2018cites this paper
• Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer

  2018cites this paper
• Integrated approach to study Ras-dependent cancer metabolic rewiring in mouse fibroblasts

  2017cites this paper
• Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene

  2017cites this paper
• The role of anaplastic lymphoma kinase in pediatric cancers

  2017cites this paper
• ALK: a tyrosine kinase target for cancer therapy

  2017cites this paper
• Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer

  2017cites this paper
• Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.

  2017cites this paper
• Targeting ALK: Precision Medicine Takes on Drug Resistance.

  2017cites this paper
• Molecular biological characteristics of ALK-positive anaplastic large cell lymphoma

  2017cites this paper
• ALK gene alterations in cancer: biological aspects and therapeutic implications.

  2017cites this paper
• Understanding and targeting resistance mechanisms in NSCLC

  2017cites this paper
• Rôle et régulation de l'autophagie dans les lymphomes anaplasiques à grandes cellules ALK positifs

  2016cites this paper
• The role of the ALK receptor in cancer biology.

  2016cites this paper
• ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern

  2016cites this paper
• Activity and mechanism of action of histone deacetylase inhibitors in synovial sarcoma

  2016cites this paper
• Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors

  2015cites this paper
• Key contribution of eIF4H-mediated translational control in tumor promotion

  2015cites this paper
• Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.

  2015cites this paper
• ALK‐positive primary cutaneous T‐cell‐lymphoma (CTCL) with unusual clinical presentation and aggressive course

  2015cites this paper
• Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3.

  2015cites this paper
• Original Article Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature

  2015cites this paper
• ALK biology in health and disease

  2015cites this paper
• The ALK Receptor Family

  2015cites this paper
• Intracellular Trafficking and Tropomyosin-receptor Kinase Fused Gene (TRK-fused gene, TFG)

  2014cites this paper
• CLTC‐ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm

  2014cites this paper
• Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase

  2014cites this paper
• Novel clathrin activity: developments in health and disease

  2014cites this paper
• Targeting tropomyosin-receptor kinase fused gene in cancer.

  2014cites this paper
• Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

  2014cites this paper
• ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.

  2013cites this paper
• Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.

  2013cites this paper
• Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma

  2013cites this paper
• Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma

  2013cites this paper
• Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

  2013cites this paper
• tyrosine kinase NPM-ALK A ''liaison dangereuse'' between AUF1/hnRNPD and the oncogenic

  2013cites this paper
• STAT3 Pathway Is Activated in ALK-positive Large B-cell Lymphoma Carrying SQSTM1-ALK Rearrangement and Provides a Possible Therapeutic Target

  2013cites this paper
• Anaplastic lymphoma kinase as a therapeutic target

  2012cites this paper
• Molecular Subtyping of Lung Carcinomas for Targeted Therapy

  2012cites this paper
• Neuroblastome, résistance in vivo à l'irinotecan et voie de signalisation ALK

  2012cites this paper
• Title Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma

  2012cites this paper
• Anaplastic Lymphoma Kinase mutations and downstream signalling

  2012cites this paper
• NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases

  2012influential citation
• ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment

  2012cites this paper
• ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma

  2012cites this paper
• Searching for molecular targets in sarcoma.

  2012cites this paper
• Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies

  2012cites this paper
• Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.

  2012cites this paper
• The Nucleophosmin-Anaplastic Lymphoma Kinase Oncogene Interacts, Activates, and Uses the Kinase PIKfyve to Increase Invasiveness*

  2011cites this paper
• β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

  2011influential citation
• Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

  2011cites this paper
• A novel KIF5B‐ALK variant in nonsmall cell lung cancer

  2011cites this paper
• Novel mRNA-containing cytoplasmic granules in ALK-transformed cells

  2011influential citation
• Anaplastic large cell lymphoma: twenty-five years of discovery.

  2011cites this paper
• Clathrin Heavy Chain Gene Fusions Expressed in Human Cancers: Analysis of Cellular Functions

  2011influential citation
• Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

  2011cites this paper
• Looking for the functions of RNA granules in ALK-transformed cells

  2011cites this paper
• HuR-Mediated Control of C/EBPβ mRNA Stability and Translation in ALK-Positive Anaplastic Large Cell Lymphomas

  2011cites this paper
• ALK rearrangement in sickle cell trait‐associated renal medullary carcinoma

  2011influential citation
• Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination

  2011cites this paper
• Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas

  2011cites this paper
• Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

  2010cites this paper
• Development of Diverse Tools for Pigment Cell Research and Drug Screening in Zebrafish

  2010cites this paper
• ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

  2010cites this paper
• Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2

  2010cites this paper
• Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.

  2010cites this paper
• Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion.

  2010cites this paper
• Molecular Pathways Inhibition of ALK Signaling for Cancer Therapy

  2009cites this paper
• Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.

  2009cites this paper
• Anaplastic lymphoma kinase: signalling in development and disease

  2009cites this paper